Adam Mostafa

Adam joined Sitryx from X4 Pharmaceuticals (NASDAQ: XFOR), a hematology and immunology focused rare disease company, where he served as Chief Financial Officer and Head of Business Development and helped lead the company from clinical development to FDA approval and launch of XOLREMDI(r). Prior to joining X4, Mr. Mostafa served as Chief Financial Officer and Head of Business Development of Abpro Corporation, a biotechnology company focused on antibody therapeutics. Prior to that, Mr. Mostafa held a number of investment banking and portfolio management positions, including Managing Director in the healthcare investment banking group at Cantor Fitzgerald, Senior Vice President in the healthcare investment banking group at Needham & Company, Vice President at CRT Capital Group, and portfolio management associate in the global stock selection group at AQR Capital. Adam began his career as an analyst in the healthcare investment banking group at Salomon Smith Barney. Adam is also on the Board of Directors of Satellos Biosciences (TSX: MSCL) and Precision Biologics. Mr. Mostafa holds a A.B. in Economics from Brown University.